Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastroenterol. Feb 28, 2022; 28(8): 825-839
Published online Feb 28, 2022. doi: 10.3748/wjg.v28.i8.825
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 The study design flow-diagram. CRC: Colorectal cancer; TSGH: Tri-Service General Hospital; SUMF2: Sulfatase modifying factor 2; ADAMTS5: ADAM metallopeptidase with thrombospondin type 1 motif 5; PXDN: Peroxidasin; RFS: Recurrence-free survival; PFS: Progression-free survival; OS: Overall survival.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 The methylation-specific polymerase chain reaction results of PXDN gene in colorectal cancer patients. Negative control, positive control and sterile water represent unmethylation-specific reaction, methylation-specific reaction and no contaminant reaction for polymerase chain reaction, respectively. CRC: Colorectal cancer.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 The location of informative CpG sites in the (A) SUMF2 and (B) ADAMTS5 promoter region.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Kaplan–Meier survival curves depicting the effect of hypermethylation and hypomethylation of SUMF2 at CpG_3+CpG_7 from tumor tissue on 5-year (A) progression-free survival and (B) overall survival of colorectal cancer patients.
Figure 5
Open in New Tab Full Size Figure Download Figure
Figure 5 Kaplan–Meier survival curves depicting the effect of hypermethylation and hypomethylation of ADAMTS5 at (A) CpG_2 and (B) CpG_13 from normal tissue on 5-year recurrence-free survival of colorectal cancer patients.